Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "Pfizer"

219 News Found

Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
News | January 18, 2022

Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology

Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines


Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron
Biotech | January 07, 2022

SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron

Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry
News | December 30, 2021

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness


Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


NMPA approves CStone's NDA for Cejemly
Drug Approval | December 21, 2021

NMPA approves CStone's NDA for Cejemly

The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients


Gamaleya claims the Sputnik V perfect booster against Omicron
News | December 20, 2021

Gamaleya claims the Sputnik V perfect booster against Omicron

Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response


DaVita research indicates effectiveness of mRNA vaccine in dialysis patients
News | November 30, 2021

DaVita research indicates effectiveness of mRNA vaccine in dialysis patients

Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively


U.S. FDA gives green light to Moderna and J&J booster doses
Drug Approval | October 21, 2021

U.S. FDA gives green light to Moderna and J&J booster doses

The authority also allowed mix and match of booster doses once the primary vaccine has been administered.